Stock Events

Stock Events

Search...

Newron Pharmaceuticals Spa.

$9

7

+$0+0% Wednesday 16:32

Statistics

Day High

12

Day Low

12

52W High

12

52W Low

5.22

Volume

100

Avg. Volume

550

Mkt Cap

162.39M

P/E Ratio

0

Dividend Yield

-

Dividend

-

Upcoming

Earnings

19SepExpected

Q2 2016

Q4 2016

Q2 2017

Q4 2017

Q2 2022

Q4 2023

Q2 2024

-1.12

-0.72

-0.31

0.09

Expected EPS

N/A

Actual EPS

-0.463188813192

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NWPHF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Biogen Inc. focuses on discovering, developing, and delivering therapies for neurological and neurodegenerative diseases, directly competing with Newron's focus on central nervous system treatments.

Novartis AG operates in the pharmaceuticals sector focusing on innovative medicines, including treatments for neurological conditions, making it a direct competitor.

Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products including treatments for neurological disorders, competing in the same therapeutic areas as Newron.

Merck & Co., Inc. offers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, including efforts in neurology and neurodegenerative diseases.

Eli Lilly and Company is engaged in the discovery, development, and marketing of pharmaceutical products, with a strong focus on neuroscience, making it a competitor.

Roche Holding AG focuses on pharmaceuticals and diagnostics with a strong emphasis on neuroscience, including multiple sclerosis and spinal muscular atrophy treatments.

Teva- Pharmaceutical Industries

Teva Pharmaceutical Industries Limited specializes in generic and specialty medicines, including CNS treatments, directly competing with Newron's product offerings.

AbbVie Inc. focuses on pharmaceuticals including neuroscience, where it is developing treatments for several neurological conditions, competing with Newron.

Johnson & Johnson

Johnson & Johnson operates in the pharmaceutical, medical devices, and consumer health sectors, with its pharmaceutical segment developing treatments for neurological diseases.

AstraZeneca PLC is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including for neurological diseases, competing with Newron.

About

Pharmaceuticals: Major

Health Technology

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.

Show more...

CEO

Stefan Weber

Employees

22

Country

IT

ISIN

IT0004147952

Listings